|
Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib. |
|
|
Consulting or Advisory Role - Amgen; Sirtex Medical; Taiho Pharmaceutical |
Speakers' Bureau - Genentech |
Research Funding - Biomarin (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst) |
Travel, Accommodations, Expenses - Amgen; Genentech; Lilly |
|
|
Consulting or Advisory Role - Chugai Pharma; EMD Serono; G1 Therapeutics; Lilly; Takeda; Tesaro; Vertex |
Research Funding - Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Cellceutix (Inst); Covidien (Inst); Cyclacel (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly; Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Sanofi (Inst); Tensha Therapeutics (Inst); Vertex (Inst) |
|
|
No Relationships to Disclose |
|
Rebecca Sophie Kristeleit |
Honoraria - AstraZeneca; Clovis Oncology; Roche/Genentech |
Consulting or Advisory Role - Clovis Oncology; Lytix Biopharma; Roche/Genentech; Sotio |
Travel, Accommodations, Expenses - Basilea; Clovis Oncology; PiQuR |
|
|
Stock and Other Ownership Interests - Amarin Corporation; Antares Pharmaceuticals; ARIAD; Spectrum Pharmaceuticals |
Consulting or Advisory Role - Ipsen; New B Innovation |
Research Funding - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - AstraZeneca (Inst); Bayer (Inst); EMD Serono (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Roche (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; NanoString Technologies; Novartis; Pfizer; Roche |
|
|
Consulting or Advisory Role - Janssen; Merck; Takeda |
Research Funding - Advaxis (Inst); Amgen (Inst); EMD Serono (Inst); Ignyta (Inst); Immunocore (Inst); Incyte (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst); TC Biopharm (Inst) |
Travel, Accommodations, Expenses - Takeda |
|
|
Honoraria - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Novartis; Pfizer; Sanofi |
Speakers' Bureau - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer |
Research Funding - Astellas Pharma; Exelixis; Novartis; Pfizer |
|
|
Stock and Other Ownership Interests - PharmaMar |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Caris MPI; GlaxoSmithKline; MSD; NanoString Technologies; Novartis; Roche/Genentech |
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche (Inst) |
Patents, Royalties, Other Intellectual Property - Pharmar |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis |
|
|
|
Stock and Other Ownership Interests - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; CASI Pharmaceuticals; Deciphera; Karyopharm Therapeutics; Lilly; Novartis; Pfizer; Roche |